Please check your data on survival rates for AML. I believe overall rates of NED 5 years post-diagnosis are closer to 45%, although given the fairly new system of risk stratification, long-term survival rates vary depending on subtype. (I believe APL, aka AML M3, is close to 80%.)
No cancer--including the most treatable cancers such as pediatric ALL and Hodgkins lymphoma--is 97% curable. This sends a misleading message to the general public, and healthcare professionals unfamiliar with oncology, regarding the actual impact of cancer.
However, I do want to thank you for your support of long-term followup for cancer survivors. As the parent of a pediatric AML survivor, I daily live with concerns regarding my child's future health.
I'd like to propose a new Family Practice subspecialty: Survivorship Medicine. Practitioners would be trained to be aware of potential late effects from pediatric or adult cancer treatment and know when to refer to specialists to effectively treat (and track!) the late effects.
Please check your data on survival rates for AML. I believe overall rates of NED 5 years post-diagnosis are closer to 45%, although given the fairly new system of risk stratification, long-term survival rates vary depending on subtype. (I believe APL, aka AML M3, is close to 80%.)
No cancer--including the most treatable cancers such as pediatric ALL and Hodgkins lymphoma--is 97% curable. This sends a misleading message to the general public, and healthcare professionals unfamiliar with oncology, regarding the actual impact of cancer.
However, I do want to thank you for your support of long-term followup for cancer survivors. As the parent of a pediatric AML survivor, I daily live with concerns regarding my child's future health.
I'd like to propose a new Family Practice subspecialty: Survivorship Medicine. Practitioners would be trained to be aware of potential late effects from pediatric or adult cancer treatment and know when to refer to specialists to effectively treat (and track!) the late effects.
Thank you!